Voortman, J., Goto, A., Mendiboure, J., Sohn, J.J., Schetter, A.J., Saito, M., Dunant, A., Pham, T.C., Petrini, I., Lee, A., Khan, M.A., Hainaut, P., Pignon, J.P., Brambilla, E., Popper, H.H., Filipits, M., Harris, C.C. and Giaccone, G. (2010) MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. Cancer Research, 70, 8288-8298. http://dx.doi.org/10.1158/0008-5472.CAN-10-1348

has been cited by the following article:

• TITLE: Prognostic Role of miR-205 in Early-Stage (T1N0) Non-Small Cell Lung Cancer

  AUTHORS: Laura Boldrini, Mirella Giordano, Adele Servadio, Greta Alì, Alice Cocco, Marco Lucchi, Pietro Bertoglio, Franca Melfi, Alfredo Mussi, Gabriella Fontanini

  KEYWORDS: Non-Small Cell Lung Cancer, miR-21, let-7g, miR-205, Prognosis

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.2, June 20, 2014

  ABSTRACT: Background: Published data have shown that microRNAs (miRNAs) could play a potential role as diagnostic and prognostic indicators in cancers. Data for the predictive value of miRNA let-7, miR-21, and miR-205 are inconclusive. The aim of the present analysis was therefore to evaluate the expression and the prognostic role of the above mentioned miRNAsin early-stage(T1N0) NSCLC patients. Methods: Quantification of let-7g, miR-21, and miR-205 expression was carried out into 105 early-stage NSCLC by quantitative Real Time-PCR (qRT-PCR).Results: a significant association between the low miR-205 expression and ADC histotype (p0.0001) compared to SCCwas found; moreover, survival analysis showed thattumors with a highmiR-205 expression had a significantly shorter mean PFS and OS compared to the patients with a low expression of this miRNA (p = 0.02 and p = 0.03, respectively). No other statistically significant correlations were observed between the analysed miRNAs and the main clinico-pathological characteristics of the NSCLC patients. Conclusion: The results indicated that miR-205 could represent a useful marker in the prognostic management of the early-stage (T1N0) NSCLC patients.